Form 4: Tyra Biosciences COO Daniel Bensen Reports Stock Sales

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, reported the sale of company stock on June 7 and June 10, 2024, according to a Form 4 filing with the SEC.

Summary

• Daniel Bensen, the Chief Operating Officer of Tyra Biosciences, filed a Form 4 with the SEC.
• The filing reports the sale of 200 shares of common stock on June 7, 2024, at a price of $20 per share.
• An additional 3,502 shares were sold on June 10, 2024, at a weighted average price of $20.0014 per share, with prices ranging from $20.00 to $20.03.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 7, 2022.
• Following these transactions, Bensen directly owns 427,981 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales by an executive under a pre-existing trading plan. It doesn't inherently indicate positive or negative news about the company.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. However, large or frequent sales can sometimes be viewed negatively by investors.

Stakeholder Impact

• Shareholders may react to the news of the stock sales, although the impact is likely to be minimal given the pre-planned nature of the transactions.

Key Dates